DarioHealth (NASDAQ:DRIO) Issues Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Key Points

• DarioHealth beat EPS estimates, reporting a quarterly loss of $0.85 per share versus the expected $1.22 loss, but revenue of $5.18 million fell short of the $5.92 million consensus.
• Revenue declined year over year to $5.2 million, although gross margin improved to 62%, operating expenses fell 21%, and the net loss narrowed 39% to $7.9 million.
• The company reported approximately $13.1 million in contracted and late-stage annual recurring revenue and increased pro forma cash to $36.8 million after a July financing, while expanding into GLP-1, women’s health, and sleep programs.

DarioHealth (NASDAQ:DRIO - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.37, FiscalAI reports. The company had revenue of $5.18 million for the quarter, compared to analyst estimates of $5.92 million. DarioHealth had a negative return on equity of 60.52% and a negative net margin of 192.23%.

Here are the key takeaways from DarioHealth's conference call:

• Revenue declined to $5.2 million from $5.6 million in Q1 and $5.4 million a year ago, reflecting implementation timing and the company’s exit from pharmaceutical-services revenue. Management expects momentum to improve in Q3 and Q4, but most contracted revenue is not expected to contribute until 2027.
• DarioHealth ended Q2 with approximately $13.1 million in contracted and late-stage annual recurring revenue, more than 80% of it multi-condition, and reported over 180 signed employer and health-plan accounts. About 75% of new accounts now come through channel partners, which management says is reducing customer-acquisition costs and sales-cycle times.
• Financial efficiency improved, with gross margin rising to 62%, operating expenses falling 21% year over year, and net loss improving 39% to $7.9 million. Management expects incremental revenue from existing implementations, AI-enabled engagement, and new care offerings to generate meaningful operating leverage.
• The company launched an integrated GLP-1 program and introduced women’s health and sleep programs, expanding its provider-backed care and multi-condition platform. Dario expects DarioIQ to increase recurring revenue from existing customers by approximately 10%–15% over time through improved engagement, retention, and outcomes.
• Pro forma cash increased to $36.8 million following a July registered-direct financing, providing additional runway to execute on commercial opportunities and pursue the company’s path toward cash-flow positivity.

DarioHealth Price Performance

DRIO traded up $0.07 during trading on Tuesday, hitting $7.72. The company's stock had a trading volume of 37,387 shares, compared to its average volume of 15,220. The company has a current ratio of 3.07, a quick ratio of 2.62 and a debt-to-equity ratio of 0.50. DarioHealth has a twelve month low of $5.84 and a twelve month high of $17.74. The business's fifty day simple moving average is $7.10 and its 200 day simple moving average is $8.33. The firm has a market capitalization of $56.70 million, a price-to-earnings ratio of -0.87 and a beta of 1.11.

Insider Activity

In related news, Director Dennis Matheis purchased 14,430 shares of the company's stock in a transaction that occurred on Thursday, July 23rd. The shares were purchased at an average price of $6.93 per share, with a total value of $99,999.90. Following the purchase, the director owned 43,026 shares of the company's stock, valued at $298,170.18. The trade was a 50.46% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.50% of the stock is owned by company insiders.

Institutional Trading of DarioHealth

Several institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new stake in DarioHealth during the 4th quarter worth approximately $35,000. Geode Capital Management LLC lifted its stake in shares of DarioHealth by 167.9% in the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company's stock worth $564,000 after buying an additional 31,063 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company's stock worth $42,000 after acquiring an additional 43,513 shares during the last quarter. Institutional investors and hedge funds own 33.39% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on DRIO. Stifel Nicolaus reissued a "buy" rating and set a $10.00 price target on shares of DarioHealth in a research report on Thursday, May 14th. TD Cowen reissued a "hold" rating and set a $11.00 target price on shares of DarioHealth in a report on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DarioHealth in a report on Friday, July 10th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $10.50.

DarioHealth Company Profile

DarioHealth NASDAQ: DRIO is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source